News Bayer moves Hyrnuo into frontline lung cancer treatment Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News Amgen's Imdelltra scores again in small cell lung cancer Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.
News BMS eyes role for new CAR-T in post-BCMA multiple myeloma BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.
News FDA overrides adcomm and approves AZ's oral SERD The FDA has gone against the advice of its own expert advisors and approved AstraZeneca's Etcamah as a frontline treatment for breast cancer.
News AbbVie's cancer TCE etentamig hits the mark in myeloma AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
News Hutchmed rises on $1.3bn KRAS licensing deal with GSK GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.